ArticleAIDS and behavior2026
Under the Influence: Alcohol, Substance Use and Treatment Adherence in Youth Living with HIV in the Global Adolescent and Young Adult Network of IeDEA (AYANI) Cohort.
Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
Abstract
Alcohol and substance use in youth living with HIV (YLHIV) can influence health and treatment outcomes. We assessed substance use and associations with antiretroviral therapy (ART) adherence among YLHIV. The Adolescent and Young Adult Network of IeDEA enrolled YLHIV (15–24 years old) receiving ART (2021–2024) from 6 global regions. We assessed biopsychosocial experiences with validated tools; adherence with self-reported missed medication doses and unsuppressed viral load (VL > 1,000 copies/ml); and substance use by point-of-care urine tests and Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) tool. Among 694 YLHIV, 53% female, median enrolment 20 years old (IQR 18–22), 83% had perinatally-acquired HIV, and 71% received Integrase Inhibitor-based ART. Half (49%) reported missing medication doses and 14% had unsuppressed VL. Any prior alcohol use (47%) was more common than other substances, where cannabis (12%) and sedatives/benzodiazepines (3.9%) contributed. Recent moderate/high-risk alcohol and other substance use were reported by 9.1% of YLHIV. YLHIV with positive urine tests had not reported recent use of alcohol (n = 17/46; 37%), cannabis (n = 12/32; 38%) and benzodiazepines (n = 13/13, 100%). Moderate/high-risk alcohol and other substance use were associated with self-reported adherence difficulties (adjusted odds ratio(aOR) 2.37, 95% CI 1.28–4.38; and aOR 2.13, 95% CI 1.18–3.85) but not unsuppressed VL (aOR 0.80, 95% CI 0.34–1.88; and aOR 1.61, 95% CI 0.79–3.29). Moderate/high-risk alcohol and/or substance use was reported by 15% of YLHIV and was associated with self-reported adherence difficulties. Discrepancies between point-of-care tests and self-reported use suggest alcohol/substance use is underestimated. Enhanced screening and interventions targeting substance use are recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.